With An Import Alert, India's Aurobindo Reels Under U.S. FDA Glare; Four Pfizer Products Impacted
This article was originally published in PharmAsia News
MUMBAI - In what is being described as a body blow to the reputation of Indian drug companies, U.S. FDA imposed an import alert against one manufacturing site of Aurobindo Pharma located near the central Indian city of Hyderabad
You may also be interested in...
India’s Aurobindo Pharma lands U.S. FDA approval of generic Seroquel despite warning letter issued last year.
MUMBAI - Daiichi-Sankyo controlled Ranbaxy Laboratories Ltd. took analysts in India by surprise with a forecast of a very conservative growth target that did not factor in any upside from a possible launch of a generic version of Lipitor (atorvastatin) in the U.S
As Pfizer Deal Speeds Up, Aurobindo Tangos With AstraZeneca For Branded Generics Play In Emerging Markets
MUMBAI - India's Aurobindo Pharma is turning out to be a partner of choice for Big Pharma companies that intend to dig aggressively into emerging markets with a branded generics product portfolio